Sopharma AD stock (BG11SOSOBT18): Established pharmaceutical player from Bulgaria

Sopharma AD, listed on the Bulgarian Stock Exchange under ticker 5SO, reported steady operations in its latest available financials. The company, known for its production of over 100 medicinal products, focuses on generics and active pharmaceutical ingredients. According to its investor relations page as of 05/13/2026, Sopharma operates multiple production sites certified under EU GMP standards.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Sopharma AD: core business model

Sopharma AD is one of Bulgaria's largest pharmaceutical companies, established in 1933. It specializes in the development, production, and distribution of generic medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. The company exports to over 40 countries, with a strong presence in Eastern Europe and the Commonwealth of Independent States (CIS). Its business model relies on cost-efficient manufacturing and regulatory compliance to compete in price-sensitive markets.

Production facilities in Sofia and Lovetch produce tablets, capsules, ointments, and injectables. Sopharma holds EU GMP certification, enabling exports to the European Union. For US investors, the company's exposure to emerging markets offers diversification, though currency risks in BGN and RUB apply.

Main revenue and product drivers for Sopharma AD

Key products include generics like metformin for diabetes and antibiotics such as amoxicillin. In 2023 full-year results published in March 2024, revenue reached approximately 320 million BGN, driven 60% by exports, per company reports as of 03/2024. Cardiovascular and anti-infective drugs form core pillars.

APIs contribute about 20% of sales, with production of substances like caffeine and papaverine. Branded lines such as Magne B6 add margin through local dominance in Bulgaria. US relevance stems from potential supply chain roles in generic sourcing.

Industry trends and competitive position

The global generics market grows at 5-7% CAGR through 2030, per Statista data published 2024, fueled by patent cliffs and cost pressures on healthcare. Sopharma benefits as a low-cost Eastern European producer, competing with Indian and Israeli peers.

In Bulgaria, it holds 10-15% market share. Challenges include raw material inflation and regulatory hurdles for new markets. For US investors, Sopharma represents value in underserved pharma segments.

Why Sopharma AD matters for US investors

Listed on BSE, Sopharma trades as a GDR on some platforms, offering indirect US access. Its focus on affordable generics aligns with US payer demands for lower drug prices. Exposure to stable Eastern European pharma demand provides a hedge against US market volatility.

Conclusion

Sopharma AD remains a solid player in the generics space with established export channels and a broad product range. While recent specific catalysts are limited, its operational stability and market positioning support ongoing interest. Investors tracking Eastern European pharma may find value in monitoring volume growth and margin trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.